Clinical Trial Update: 124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on 124I-p5+14 injection safety in systemic amyloidosis reported as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Amyloidosis

Drugs mentioned

• 124I-p5+14 (Iodine-124 labeled p5+14)

Snippet

Sponsor: University of Tennessee Graduate School of Medicine | Conditions: Systemic Amyloidosis | Phase 1, Phase 2 | Status: COMPLETED